Print Email Facebook Twitter Contrasting responses to interferon β-1b treatment in relapsing-remitting multiple sclerosis: Does baseline interleukin- 12p35 messenger RNA predict the efficacy of treatment? Title Contrasting responses to interferon β-1b treatment in relapsing-remitting multiple sclerosis: Does baseline interleukin- 12p35 messenger RNA predict the efficacy of treatment? Author Boxel van-Dezaire, A.H.H. Trigt van-Hoff, S.C.J. Killestein, J. Schrijver, H.M. van Houwelingen, J.C. Polman, C.H. Nagelkerken, L. TNO Preventie en Gezondheid Publication year 2000 Abstract Interferon (IFN)-β treatment is effective in relapsing-remitting multiple sclerosis (RR-MS) via an as yet unidentified mechanism. In the present study, we investigated whether the expression of messenger RNA (mRNA) encoding the interleukin (IL)-12 subunits p40 and p35, IL-12 receptor chains, IL-18, tumor necrosis factor-α (TNFα), IFNγ, IL-10, IL-4, or transforming growth factor-β in unstimulated whole blood of 26 RR-MS patents changed during 6 months of IFNβ-1b treatment. In these patients, a significant change was found in TNFα mRNA, whereas changes in IL-12 receptor-β2 and IL-10 mRNA showed a trend. IFNβ-1b-related changes in cytokine mRNA expression were next evaluated in clinical subgroups of RR-MS patents classified as either clinical responders or nonresponders on the basis of Expanded Disability Status Scale progression and the number of relapses and steroid interventions needed in the 2 years before initiation of treatment compared with the 2 years after initiation of treatment. These subgroups showed different response patterns to IFNβ-1b treatment with respect to IL-10, TNFα, and IL-18 only. Surprisingly, clinical responders displayed no change in these cytokines, whereas nonresponders showed a decrease in TNFα and IL-18 mRNA as well as a transient increase in IL-10 mRNA. Baseline levels of IL-12p35 mRNA were lower in the responders compared with the nonresponders: this marker correctly predicted the clinical outcome in 81% of the 26 patents under investigation. Chemicals/CAS: interferon beta 1a, 145258-61-3; interferon beta-1b, 145155-23-3; Interferon-beta, 77238-31-4; Interleukin-12, 187348-17-0; RNA, Messenger Subject HealthGamma interferonInterferon beta serineInterleukin 10Interleukin 12Interleukin 12 receptorInterleukin 18Messenger RNAProtein p35Protein p40Clinical articleDisabilityDisease classificationDNA synthesisDrug efficacyGene expressionMultiple sclerosisPredictionRating scaleRecurrent diseaseTreatment outcomeAdultFemaleHumansInterferon-betaInterleukin-12MaleMultiple Sclerosis, Relapsing-RemittingPredictive Value of TestsRNA, MessengerTime Factors To reference this document use: http://resolver.tudelft.nl/uuid:a949cd0e-e1bb-41a5-98d6-c2d96e9235bf DOI https://doi.org/10.1002/1531-8249(200009)48:3<313::aid-ana5>3.0.co;2-9 TNO identifier 235665 ISSN 0364-5134 Source Annals of Neurology, 48 (3), 313-322 Document type article Files To receive the publication files, please send an e-mail request to TNO Library.